BMC Neurology · 2004 · 29 citations · 15 references
MedicineNeurologyPharmacotherapyNeurologic PharmacotherapyPain ManagementPain MedicineIntrathecal Drug DeliveryMultiple SclerosisMultiple Sclerosis PharmacotherapyMultiple Sclerosis RehabilitationNeurological AssessmentNeurological RehabilitationMethylprednisolone UseMultiple Sclerosis Symptom ManagementMultiple Sclerosis TherapyPost-treatment RehabilitationPrimary Progressive Multiple Sclerosis TreatmentSecondary Progressive Multiple Sclerosis TreatmentWalking Distance Analysis
BACKGROUND: There are controversial results on the efficacy of the abandoned, intrathecal predominant methylprednisolone application in multiple sclerosis (MS) in contrast to the proven effectiveness in intractable postherpetic neuralgia. METHODS: We performed an analysis of the efficacy of the application of 40 mg of the sustained release steroid triamcinolone acetonide (TCA). We intrathecally injected in sterile saline dissolved TCA six times within three weeks on a regular basis every third day in 161 hospitalized primary and predominant secondary progressive MS patients with spinal symptoms. The MS patients did not experience an acute onset of exacerbation or recent distinct increased progression of symptoms. We simultaneously scored the MS patients with the EDSS and the Barthel index, estimated the walking distance and measured somatosensory evoked potentials. Additionally the MS patients received a standardized rehabilitation treatment. RESULTS: EDSS score and Barthel index improved, walking distance increased, latencies of somatosensory evoked potentials of the median and tibial nerves shortened in all MS patients with serial evaluation (p < 0.0001 for all variables). Side effects were rare, five patients stopped TCA application due to onset of a post lumbar puncture syndrome. CONCLUSIONS: Repeated intrathecal TCA application improves spinal symptoms, walking distance and SSEP latencies in progressive MS patients in this uncontrolled study. Future trials should evaluate the long-term benefit of this invasive treatment.
15
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Robert Zivadinov, Richard A. Rudick, Roberto De Masi et al. · Neurology · 2001 · 346 citations
Intrathecal Methylprednisolone for Intractable Postherpetic Neuralgia
Naoki Kotani, Tetsuya Kushikata, Hiroshi Hashimoto et al. · New England Journal of Medicine · 2000 · 306 citations · Full text
Medicine, Neurology, Neuroscience +13